Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.

ABSTRACT:

Objective

To assess the efficacy and safety of the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin in patients of different ethnicities.

Design setting and patients

Post hoc analysis of data pooled from four randomized, placebo-controlled, phase 3 studies of adults with inadequately controlled type 2 diabetes mellitus (T2DM).

Interventions

Once daily oral canagliflozin 100 mg or 300 mg, or placebo.

Main outcome measures

Efficacy endpoints included change from baseline in HbA1c, body weight (BW), systolic blood pressure (SBP), and lipids at week 26; safety and tolerability were assessed by adverse event reports.

Results

Of the 2,313 patients included in this pooled analysis, 609 self-identified as Hispanic/Latino. Hispanic/Latino patients

SUBMITTER: Davidson JA 

PROVIDER: S-EPMC4836903 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature